US biotechnology start-up LivFul has secured a $1.5m investment to expand its work saving lives from malaria and other insect-borne diseases, and to support the company’s growth plans.    The company’s major markets are now opening up following the pandemic, with interest in Livful’s Enhanced Insect Repellent ramping up. Livful is currently focussing its business development […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!